IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more
IRLAB Therapeutics AB (publ) (IRLAB-A) - Net Assets
Latest net assets as of September 2025: Skr54.21 Million SEK
Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has net assets worth Skr54.21 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr170.55 Million) and total liabilities (Skr116.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr54.21 Million |
| % of Total Assets | 31.79% |
| Annual Growth Rate | 2.46% |
| 5-Year Change | -90.62% |
| 10-Year Change | -64.54% |
| Growth Volatility | 84.93 |
IRLAB Therapeutics AB (publ) - Net Assets Trend (2013–2024)
This chart illustrates how IRLAB Therapeutics AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IRLAB Therapeutics AB (publ) (2013–2024)
The table below shows the annual net assets of IRLAB Therapeutics AB (publ) from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr32.63 Million | -71.81% |
| 2023-12-31 | Skr115.76 Million | -60.20% |
| 2022-12-31 | Skr290.83 Million | -27.20% |
| 2021-12-31 | Skr399.48 Million | +14.83% |
| 2020-12-31 | Skr347.88 Million | +91.32% |
| 2019-12-31 | Skr181.83 Million | -14.42% |
| 2018-12-31 | Skr212.48 Million | +37.08% |
| 2017-12-31 | Skr155.00 Million | +49.20% |
| 2016-12-31 | Skr103.89 Million | +12.89% |
| 2015-12-31 | Skr92.03 Million | +3.90% |
| 2014-12-31 | Skr88.57 Million | +254.41% |
| 2013-12-31 | Skr24.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IRLAB Therapeutics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65860000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.04 Million | 3.18% |
| Other Comprehensive Income | Skr1.00K | 0.00% |
| Other Components | Skr690.20 Million | 2114.98% |
| Total Equity | Skr32.63 Million | 100.00% |
IRLAB Therapeutics AB (publ) Competitors by Market Cap
The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asmallworld AG
SW:ASWN
|
$9.55 Million |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
$9.55 Million |
|
BLUELAKE MINERAL AB
F:5KG0
|
$9.56 Million |
|
Vertiqal Studios Corp.
PINK:VERTF
|
$9.56 Million |
|
Almondz Global Securities Limited
NSE:ALMONDZ
|
$9.55 Million |
|
PT Puri Sentul Permai Tbk
JK:KDTN
|
$9.55 Million |
|
Prashkovsky
TA:PRSK
|
$9.55 Million |
|
Orgenesis Inc
OTCQB:ORGS
|
$9.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IRLAB Therapeutics AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 115,764,000 to 32,634,000, a change of -83,130,000 (-71.8%).
- Net loss of 83,129,000 reduced equity.
- Other comprehensive income increased equity by 1,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-83.13 Million | -254.73% |
| Other Comprehensive Income | Skr1.00K | +0.0% |
| Other Changes | Skr-2.00K | -0.01% |
| Total Change | Skr- | -71.81% |
Book Value vs Market Value Analysis
This analysis compares IRLAB Therapeutics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.53x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.77x to 2.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr2.07 | Skr1.59 | x |
| 2015-12-31 | Skr3.77 | Skr1.59 | x |
| 2016-12-31 | Skr4.03 | Skr1.59 | x |
| 2017-12-31 | Skr4.51 | Skr1.59 | x |
| 2018-12-31 | Skr5.46 | Skr1.59 | x |
| 2019-12-31 | Skr4.40 | Skr1.59 | x |
| 2020-12-31 | Skr7.30 | Skr1.59 | x |
| 2021-12-31 | Skr7.72 | Skr1.59 | x |
| 2022-12-31 | Skr5.61 | Skr1.59 | x |
| 2023-12-31 | Skr2.23 | Skr1.59 | x |
| 2024-12-31 | Skr0.63 | Skr1.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IRLAB Therapeutics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -254.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.85%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 4.17x
- Recent ROE (-254.73%) is below the historical average (-57.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 6.17% | 5781.48% | 0.00x | 2.10x | Skr-1.93 Million |
| 2015 | -12.92% | -412.74% | 0.03x | 1.10x | Skr-21.09 Million |
| 2016 | -41.10% | -29650.00% | 0.00x | 1.09x | Skr-53.08 Million |
| 2017 | -36.27% | -51582.57% | 0.00x | 1.05x | Skr-71.72 Million |
| 2018 | -34.87% | -411661.11% | 0.00x | 1.06x | Skr-95.35 Million |
| 2019 | -52.97% | -370453.85% | 0.00x | 1.14x | Skr-114.50 Million |
| 2020 | -26.40% | -30616.00% | 0.00x | 1.06x | Skr-126.64 Million |
| 2021 | 12.96% | 24.92% | 0.44x | 1.18x | Skr11.83 Million |
| 2022 | -39.27% | -186.80% | 0.19x | 1.11x | Skr-143.29 Million |
| 2023 | -153.62% | -3132.07% | 0.03x | 1.53x | Skr-189.42 Million |
| 2024 | -254.73% | -87.85% | 0.69x | 4.17x | Skr-86.39 Million |
Industry Comparison
This section compares IRLAB Therapeutics AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IRLAB Therapeutics AB (publ) (IRLAB-A) | Skr54.21 Million | 6.17% | 2.15x | $9.55 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |